Navigation Links
Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007

HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc. today presented preliminary results from a pilot Phase 3 trial of KW-3902, an adenosine A1 receptor antagonist in development for the treatment of patients with acute congestive heart failure (CHF), that indicate a strong trend toward efficacy for the 30 milligram dose. Patients treated with KW-3902 experienced a higher rate of improvement in dyspnea, or shortness of breath, which is a common symptom of CHF, compared to the placebo group, and the results also show that KW-3902 enhances diuresis and mitigates deterioration of renal function that is often experienced by patients undergoing standard treatment. The findings were summarized by Marco Metra, M.D., University of Brescia, Italy and Gadi Cotter, M.D., Duke University School of Medicine, in a Late-Breaking Trials Session at the European Society of Cardiology's Heart Failure Congress 2007 in Hamburg, Germany.

Drs. Metra and Cotter presented preliminary 14-day data from 276 patients out of 304 total patients enrolled in the pilot Phase 3 trial. Hospitalized patients with acute CHF with renal impairment, which was defined as having creatinine clearance of 20 to 80 milliliters per minute, were randomized to placebo or 10, 20 or 30 milligram doses of intravenous KW-3902 administered daily for up to three days. All patients also received intravenous furosemide. In the double-blind trial, 225 patients received KW-3902 and 79 patients received placebo. The trial was not designed to assess the statistical significance of effects.

The primary endpoint for the pilot Phase 3 trial was the proportion of patients in the categories of treatment failure, success or no change. Treatment success was defined as:

    -- improvement in patient-reported dyspnea within 48 hours;

    -- physician determination of patient improvement resulting in conversion

       from intravenous to oral d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Reportlinker.com announces that a new market research ... Innovations in Wound Care Devices and ... Introduction Wound ... range of sizes, shapes, stages, and types ...
... 2012 /PRNewswire-iReach/ -- Global Information, Inc. (GII) is ... Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts ... The Insulin Delivery Devices Market is ... $11 Billion by 2017 GlobalData estimated ...
Cached Medicine Technology:Innovations in Wound Care Devices and Dressings 2Innovations in Wound Care Devices and Dressings 3Innovations in Wound Care Devices and Dressings 4Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... ANN ARBOR, Mich.---Despite mounting public health concerns about obesity and ... in their ,20s consistently exercise less than young men. ... 1984 and 2006, according to a University of Michigan study ... American Journal of Public Health . The study is ...
... , , ASHEVILLE, N.C., Aug. 21 ... LD/N, explains that people who have the most success at dieting ... continually monitor their progress toward their desired outcome. SMART is an ... as "I want to lose weight" and transforms them into a ...
... , FRIDAY, Aug. 21 (HealthDay News) -- If doctors ... heart failure take their medicines correctly, hospitalizations would be ... study of 5,717 people with heart failure, the hospitalization ... reviewed by doctors and pharmacists was 45 percent lower ...
... England, Aug. 21 Medicine shortages have left patients extremely distressed, ... hospital, a Chemist+Druggist (C+D) survey has found. , , ... third said patients had already suffered because the pharmacy had had ... have reported growing difficulty getting hold of key drugs throughout 2009. ...
... Ariz., Aug. 21 Natural Health information publisher NaturalNews.com has launched a new ... NaturalPedia.com combines the wisdom of over 400 authors and 570 books that ... such as " chl o rella " or " ... NaturalPedia also pairs two-term concepts such as " cancer and lyco ...
... spot changes in the way the brain responds to ... of interest in previously enjoyable activities is a common ... that researchers can actually see in the brain. ... showed less activity in regions of the brain that ...
Cached Medicine News:Health News:Long-term exercise, healthy eating habits in young adults: U-M study 2Health News:Long-term exercise, healthy eating habits in young adults: U-M study 3Health News:Medication Review May Help With Heart Failure 2Health News:Distressed Patients Suffer Panic Attacks as UK Medicine Stocks Hit by Shortages, Chemist+Druggist Reveals 2Health News:New Online Health Encyclopedia NaturalPedia.com Distills Knowledge From Industry's Top Authors 2Health News:Depression's Effect on Pleasure Is Real 2
... Every year approximately 450,000 people in,the ... (SCD). Delivery of a defibrillation shock,quickly ... survival.,For each minute that passes, the ... The American Medical Association,and JCAHO recommend ...
The Capio CL Transvaginal Suture Capturing Device allows for a transvaginal suture fixation to Cooper's Ligament for sling procedures...
... The BioArc™ System treats female urinary stress ... using either a suprapubic (BioArcTM SP) or ... is an innovative hybrid system combining synthetic ... hybrid sling currently available. The BioArc utilizes ...
... SPARC™ Sling System utilizes a suprapubic ... incontinence due to urethral hypermobility and/or ... two curved, narrow-diameter needles and a ... suture that allows for intra-operative tension ...
Medicine Products: